Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017137949) NANOCARRIER COLOADED WITH AN INHIBITOR OF EXOCYTOSIS AND AN ACTIVE INGREDIENT
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. A nanocarrier coloaded with at least one inhibitor of exocytosis and at least one active ingredient.

2. A nanocarrier coloaded with a combination of at least one inhibitor of exocytosis and at least one active ingredient.

3. The nanocarrier according to claim 1 or 2, wherein the nanocarrier is selected from the group consisting of a metal nanocarrier, a polymer nanocarrier, a lipid nanocarrier, a carbon nanocarrier, and a protein and oligonucleotide nanocarrier.

4. The nanocarrier according to claim 3, wherein the nanocarrier is a mesoporous silica nanoparticle .

5. The nanocarrier according to any of the preceding claims, wherein the at least one inhibitor of exocytosis is dimethyl amiloride, cytochalasin A, B or D, or nocodazole.

6. The nanocarrier according to claim 5, wherein the at least one inhibitor of exocytosis is dimethyl amiloride or cytochalasin B.

7. The nanocarrier according to claim 6, wherein the at least one inhibitor of exocytosis is dimethyl amiloride.

8. The nanocarrier according to any of the preceding claims, wherein the at least one active ingredient is a drug, a plasmid or a miRNA or an siRNA.

9. The nanocarrier according to claim 8, wherein the drug is doxorubicin.

10. The nanocarrier according to any of the preceding claims for medical use.

11. The nanocarrier according to any of claims 1 to 10 for use in the treatment of a tumour.